Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Mid & small cap buck trend
Fri, 1 Aug 01:30 pm

Indian share markets continued to trade in the red in the post-noon trading session. Sectoral indices are trading mixed with IT and capital goods stocks being the biggest losers whereas realty and banking stocks are trading positive.

BSE-Sensex is down 104 points and NSE-Nifty is trading 31 points down. Both BSE Mid Cap and BSE Small Cap indices are trading up by 0.3%. The rupee is trading at 60.81 to the US dollar.

Domestic pharma stocks are trading mixed with Divis's Laboratories and Glenmark Pharma being the major gainers whereas Ranbaxy Laboratories and Indoco Remedies are trading in the red. As per a leading financial daily, Cipla has entered into an agreement with US-based Bioquiddity Inc. to sell its anesthetic applications in the European Union. The commercial collaboration is for BioQuiddity's OneDose ReadyfusOR anaesthetic product pre-filled with drug Ropivacaine for post surgical pain management. Cipla also wants to launch the anaesthetic product under its own label in German market later during year. The deal has been executed through Cipla's wholly-owned subsidiary in Europe. Cipla stock is currently trading down marginally.

Automobiles stock are trading on a mixed note today. TVS Motors and Maruti Suzuki are leading the pack of gainers, whereas Mahindra & Mahindra is trading on a weak note. India's leader in car market, Maruti Suzuki has reported its sales number for the month of July 2014. In domestic market, the company sold a total of 90,093 cars for the month, which was 20% higher over the corresponding same month of previous year. At 11,287 units, exports in July were higher by 38.4% YoY. However, sales from small cars namely Alto, A-Star and WagonR declined 14.4% YoY and mid-range SX4 witnessed decline of 27% YoY during the month. However, growth was witnessed in compact cars segment like Swift, Estilo, Ritz and Celerio which together rose by 81% YoY to 25,500 units. Its compact sedan Dzire, one of the top selling cars, rose 22% YoY to 18,000 units. The stock of Maruti is trading up by 3.6% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Mid & small cap buck trend". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.